Skip Navigation


NDT Plus Advance Access originally published online on June 16, 2008
NDT Plus 2008 1(5):313-315; doi:10.1093/ndtplus/sfn068
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
1/5/313    most recent
sfn068v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Walsh, S. B.
Right arrow Articles by Neild, G. H.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Rapamycin-induced remission of Kaposi's sarcoma is not associated with expansion of cytotoxic T-lymphocyte subsets

Stephen B. Walsh1, Shaun A. Summers2, Peter L. Amlot3, Michael T. Sheaff4 and Guy H. Neild1

1 UCL Department of Physiology and Centre for Nephrology, Royal Free and University College Medical School, Rowland Hill Street, London, UK
2 Department of Medicine, Centre for Inflammatory Disease, Monash University, Melbourne, Victoria, Australia
3 Department of Immunology, Royal Free and University College Medical School, Rowland Hill Street
4 Department of Histopathology, Bart's and the London National Health Service Trust, Royal London Hospital, Whitechapel, London, UK

Correspondence: Correspondence and offprint requests to: Stephen B. Walsh, Department of Physiology and Centre for Nephrology, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK. Tel: +44-20-7830-2765; Fax: +44-20-7830-6501; E-mail: s.walsh{at}medsch.ucl.ac.uk


  Abstract

We present a case of post-transplantation Kaposi's sarcoma (KS) successfully treated by conversion to rapamycin. Clinical and histological resolution was observed within 6 months of commencing rapamycin. Also, vascular endothelial growth factor (VEGF) staining in the biopsy samples resolved following rapamycin therapy. Interestingly there was no expansion in cytotoxic T-lymphocyte (CTL) subsets observed during this period, as might be expected if this remission was due to immune reconstitution following reduction in immunosuppression. These data suggest that the resolution of tumour with rapamycin could be the result of the antiangiogenic, antiproliferative effects of rapamycin.

Key Words: cytotoxic T-cells • Kaposi's sarcoma • rapamycin • VEGF

Received for publication March 10, 2008. Accepted for publication May 19, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.